Study of peripheral BRAFV600E mutation as a possible novel marker for papillary thyroid carcinomas

jinyoung kwak, Jong Ju Jeong, Sang Wook Kang, Seulkee Park, Jong Rak Choi, Seo Jin Park, Eunkyung Kim, Woong Youn Chung

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background The BRAFV600E mutation can be detected peripherally in the serum of patients with thyroid cancer. The purpose of this study was to establish the value of detecting the peripheral BRAFV600E mutation as a serum tumor marker in this population. Methods In this study, we obtained 94 serum samples from patients with papillary thyroid cancer positive for the BRAFV600E mutation in the tumor itself. The serum samples were analyzed for BRAFV600E mutation using real-time polymerase chain reaction (PCR). Results Sixty-seven patients (71.3%) had papillary thyroid microcarcinoma and 26 patients (27.7%) had underlying lymphocytic thyroiditis. Forty-three patients (45.7%) were found to have stage III or stage IV thyroid cancer. None of the patients had a detectable serum BRAFV600E mutation. Conclusion We were unable to identify peripheral BRAFV600E mutations in patients with papillary thyroid cancer using real-time PCR. Further studies will be needed to validate our results using various diagnostic methods.

Original languageEnglish
Pages (from-to)1630-1633
Number of pages4
JournalHead and Neck
Volume35
Issue number11
DOIs
Publication statusPublished - 2013 Jan 1

Fingerprint

Mutation
Serum
Thyroid Neoplasms
Real-Time Polymerase Chain Reaction
Autoimmune Thyroiditis
Tumor Biomarkers
Papillary Thyroid cancer
Biomarkers
Population
Neoplasms

All Science Journal Classification (ASJC) codes

  • Otorhinolaryngology

Cite this

kwak, J., Jeong, J. J., Kang, S. W., Park, S., Choi, J. R., Park, S. J., ... Chung, W. Y. (2013). Study of peripheral BRAFV600E mutation as a possible novel marker for papillary thyroid carcinomas. Head and Neck, 35(11), 1630-1633. https://doi.org/10.1002/hed.23195
kwak, jinyoung ; Jeong, Jong Ju ; Kang, Sang Wook ; Park, Seulkee ; Choi, Jong Rak ; Park, Seo Jin ; Kim, Eunkyung ; Chung, Woong Youn. / Study of peripheral BRAFV600E mutation as a possible novel marker for papillary thyroid carcinomas. In: Head and Neck. 2013 ; Vol. 35, No. 11. pp. 1630-1633.
@article{7952b78da2ed40959fc2d8fa692c7d9d,
title = "Study of peripheral BRAFV600E mutation as a possible novel marker for papillary thyroid carcinomas",
abstract = "Background The BRAFV600E mutation can be detected peripherally in the serum of patients with thyroid cancer. The purpose of this study was to establish the value of detecting the peripheral BRAFV600E mutation as a serum tumor marker in this population. Methods In this study, we obtained 94 serum samples from patients with papillary thyroid cancer positive for the BRAFV600E mutation in the tumor itself. The serum samples were analyzed for BRAFV600E mutation using real-time polymerase chain reaction (PCR). Results Sixty-seven patients (71.3{\%}) had papillary thyroid microcarcinoma and 26 patients (27.7{\%}) had underlying lymphocytic thyroiditis. Forty-three patients (45.7{\%}) were found to have stage III or stage IV thyroid cancer. None of the patients had a detectable serum BRAFV600E mutation. Conclusion We were unable to identify peripheral BRAFV600E mutations in patients with papillary thyroid cancer using real-time PCR. Further studies will be needed to validate our results using various diagnostic methods.",
author = "jinyoung kwak and Jeong, {Jong Ju} and Kang, {Sang Wook} and Seulkee Park and Choi, {Jong Rak} and Park, {Seo Jin} and Eunkyung Kim and Chung, {Woong Youn}",
year = "2013",
month = "1",
day = "1",
doi = "10.1002/hed.23195",
language = "English",
volume = "35",
pages = "1630--1633",
journal = "Head and Neck",
issn = "1043-3074",
publisher = "John Wiley and Sons Inc.",
number = "11",

}

kwak, J, Jeong, JJ, Kang, SW, Park, S, Choi, JR, Park, SJ, Kim, E & Chung, WY 2013, 'Study of peripheral BRAFV600E mutation as a possible novel marker for papillary thyroid carcinomas', Head and Neck, vol. 35, no. 11, pp. 1630-1633. https://doi.org/10.1002/hed.23195

Study of peripheral BRAFV600E mutation as a possible novel marker for papillary thyroid carcinomas. / kwak, jinyoung; Jeong, Jong Ju; Kang, Sang Wook; Park, Seulkee; Choi, Jong Rak; Park, Seo Jin; Kim, Eunkyung; Chung, Woong Youn.

In: Head and Neck, Vol. 35, No. 11, 01.01.2013, p. 1630-1633.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Study of peripheral BRAFV600E mutation as a possible novel marker for papillary thyroid carcinomas

AU - kwak, jinyoung

AU - Jeong, Jong Ju

AU - Kang, Sang Wook

AU - Park, Seulkee

AU - Choi, Jong Rak

AU - Park, Seo Jin

AU - Kim, Eunkyung

AU - Chung, Woong Youn

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Background The BRAFV600E mutation can be detected peripherally in the serum of patients with thyroid cancer. The purpose of this study was to establish the value of detecting the peripheral BRAFV600E mutation as a serum tumor marker in this population. Methods In this study, we obtained 94 serum samples from patients with papillary thyroid cancer positive for the BRAFV600E mutation in the tumor itself. The serum samples were analyzed for BRAFV600E mutation using real-time polymerase chain reaction (PCR). Results Sixty-seven patients (71.3%) had papillary thyroid microcarcinoma and 26 patients (27.7%) had underlying lymphocytic thyroiditis. Forty-three patients (45.7%) were found to have stage III or stage IV thyroid cancer. None of the patients had a detectable serum BRAFV600E mutation. Conclusion We were unable to identify peripheral BRAFV600E mutations in patients with papillary thyroid cancer using real-time PCR. Further studies will be needed to validate our results using various diagnostic methods.

AB - Background The BRAFV600E mutation can be detected peripherally in the serum of patients with thyroid cancer. The purpose of this study was to establish the value of detecting the peripheral BRAFV600E mutation as a serum tumor marker in this population. Methods In this study, we obtained 94 serum samples from patients with papillary thyroid cancer positive for the BRAFV600E mutation in the tumor itself. The serum samples were analyzed for BRAFV600E mutation using real-time polymerase chain reaction (PCR). Results Sixty-seven patients (71.3%) had papillary thyroid microcarcinoma and 26 patients (27.7%) had underlying lymphocytic thyroiditis. Forty-three patients (45.7%) were found to have stage III or stage IV thyroid cancer. None of the patients had a detectable serum BRAFV600E mutation. Conclusion We were unable to identify peripheral BRAFV600E mutations in patients with papillary thyroid cancer using real-time PCR. Further studies will be needed to validate our results using various diagnostic methods.

UR - http://www.scopus.com/inward/record.url?scp=84886378812&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886378812&partnerID=8YFLogxK

U2 - 10.1002/hed.23195

DO - 10.1002/hed.23195

M3 - Article

C2 - 23161556

AN - SCOPUS:84886378812

VL - 35

SP - 1630

EP - 1633

JO - Head and Neck

JF - Head and Neck

SN - 1043-3074

IS - 11

ER -